We start with the target.
We begin with the protein we want to modulate. A receptor driving inflammation. A surface marker on diseased tissue. An enzyme involved in tissue remodeling. The biology defines the molecule.
We design proteins
that become products.
The gap between a designed protein and a useful one is experimental proof. We build proteins to engage specific targets, run them through interaction and functional validation, and deliver candidates with complete characterization packages. Our platform operates at a fraction of the cost and timeline of traditional discovery because the computational design and the experimental validation are built as one system, not two departments.
The process
How a functional protein is born
Four steps. Weeks, not years. Measured validation on the path to product.
We design the molecule.
Our generative models create novel protein sequences for a specific target interface. These sequences have never existed before in nature or in any library.
We validate experimentally.
Interaction, function, selectivity, and developability across a structured workflow. Measured, not predicted.
We advance toward product.
We nominate the lead and run the tests that gate the next step: formulation compatibility, stability in real product conditions, and the characterization needed to move forward.
Applications
Where our molecules go
Therapeutic programs
We are advancing internal therapeutic programs in women's health, with the same platform at therapeutic-grade stringency. We drive development through preclinical and clinical milestones, with partners on specific capabilities.
Active ingredients
We develop novel protein-based actives with measured interaction and functional data. We advance them through formulation and work with ingredient partners to bring them to market.
Supported by
